Location History:
- Hanover, NH (US) (1996 - 2008)
- Etna, NH (US) (2003 - 2018)
Company Filing History:
14 out of 666 
2 out of 832,880 Years Active: 1996-2018
Title: Ta-Yuan Chang: Innovator in Neurodegenerative Disease Treatment
Introduction
Ta-Yuan Chang is a prominent inventor based in Etna, NH (US), known for his significant contributions to the field of medical research. With a total of 16 patents to his name, he has focused on developing innovative methods for treating various health conditions, particularly neurodegenerative diseases and metabolic disorders.
Latest Patents
Among his latest patents, Ta-Yuan Chang has developed a method for selectively inhibiting ACAT1 in the treatment of neurodegenerative diseases. This invention features methods for stimulating the clearance of misfolded or aggregated proteins or peptides in microglia or neurons. It aims to treat neurodegenerative diseases associated with such pathology in the brain by selectively inhibiting the expression or activity of Acyl-CoA: Cholesterol Acyltransferase 1, while not affecting Acyl-CoA: Cholesterol Acyltransferase 2. Another notable patent focuses on selectively inhibiting ACAT1 in the treatment of obesity, metabolic syndrome, and atherosclerosis. This invention presents methods for preventing and treating these related diseases by inhibiting ACAT1 activity or expression in myeloid cells.
Career Highlights
Ta-Yuan Chang has had a distinguished career, working at Dartmouth College, where he has contributed to various research initiatives. His work has been instrumental in advancing the understanding and treatment of complex health issues.
Collaborations
Throughout his career, Ta-Yuan Chang has collaborated with notable individuals, including Catherine C Y Chang and Yohei Shibuya. These collaborations have further enriched his research and innovation efforts.
Conclusion
Ta-Yuan Chang's innovative work in the field of medical research has led to significant advancements in the treatment of neurodegenerative diseases and metabolic disorders. His contributions continue to impact the scientific community and improve patient outcomes.